Not Yet RecruitingNot Applicable

Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region

United States100 participantsStarted 2026-06-01

Plain-language summary

The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.

Who can participate

Age range22 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Males or non-pregnant, non-breastfeeding females, 22 years of age or older.
✓. Intent to receive treatment for augmentation and correction of retrusion in the chin region.

Exclusion criteria

✕. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins.
✕. Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics.
✕. Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions.
✕. Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from subnasale.
✕. Any previous aesthetic procedures or implants.
✕. Presence of any disease or lesions near or on the area to be treated.

What they're measuring

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Related to Device And/Or Injection Procedure After the Month 12 Optional Retreatment

Timeframe: From Month 12 up to 3 months after optional retreatment (i.e. Month 15)

Trial details

NCT IDNCT07566286

SponsorGalderma R&D

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-11-01

Contact for this trial

Clinical Project Manager

817-961-5000 clinical.studies@galderma.com

View on ClinicalTrials.gov More Chin Augmentation trials